An epithelial microRNA upregulates airway IL-25 and TSLP expression in type 2-high asthma via targeting CD39-extracellular ATP axis

Kan Zhang[1,2,3]*, Yuchen Feng[1,2]*, Yuxia Liang[1,2], Wenliang Wu[1,2], Chenli Chang[1,2], Dian Chen[1,2], Shengchong Chen[1,2], Jiali Gao[1,2], Gongqi Chen[1,2], Lingling Yi[1,2], Dan Cheng[4], Guohua Zhen[1,2]†

[1]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; [2]Key Laboratory of Respiratory Diseases, National Health Commission of People's Republic of China, and National Clinical Research Center for Respiratory Diseases, Wuhan, China; [3]Department of Respiratory and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China; [4]Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.

* KZ and YF contributed equally to this work.

†**Correspondence to:** Guohua Zhen, Division of Respiratory and Critical Care Medicine, Tongji Hospital, Wuhan, China 430030; Email: ghzhen@tjh.tjmu.edu.cn

Short title: MicroRNA 206 upregulates IL-25 and TSLP in asthma

ABSTRACT:

Introduction: Epithelial cell-derived cytokines IL-25, IL-33 and TSLP initiate type 2 inflammation in allergic diseases. However, the signaling pathway regulating these cytokines expression remains elusive. We examined the role of epithelial microRNAs in the expression of IL-25, IL-33 and TSLP in asthma.

Methods: Differentially expressed epithelial microRNAs between type 2-low and type 2-high asthma patients were identified using microarray. The expression of microRNA (miR)-206, its target CD39, CD39's substrate ATP, and IL-25, IL-33, TSLP were measured in epithelial brushings and bronchoalveolar lavage fluid from both asthma subsets and healthy controls. The links between these measurements were functionally validated in vitro and in vivo.

Results: MiR-206 was the most highly expressed microRNA in type 2-high asthma relative to type 2-low asthma, but was downregulated in both asthma subsets compared with healthy controls. CD39, an ecto-nucleotidase degrading ATP, was a target of miR-206 and upregulated in asthma. Allergen-induced acute extracellular ATP accumulation led to miR-206 downregulation and CD39 upregulation in human bronchial epithelial cells, forming a feedback loop to eliminate excessive ATP. Airway ATP levels strongly correlated with elevated IL-25 and TSLP expression in type 2-high asthma patients. Intriguingly, airway miR-206 antagonism increased Cd39 expression, reduced ATP accumulation, suppressed Il-25, Il-33, Tslp expression and group 2 innate lymphoid cells expansion, and alleviated type 2 inflammation in a mouse model of asthma. However, airway miR-206 overexpression had opposite effects.

Conclusion: Together, epithelial miR-206 upregulates airway IL-25, TSLP expression via targeting CD39-extracellular ATP axis, which represents a novel therapeutic target in type 2-high

43   asthma.

45   **Keywords:** asthma; epithelial cells; microRNA; CD39; extracellular ATP; IL-25; TSLP

INTRODUCTION

Asthma is a heterogeneous disease with different phenotypes, endotypes, and variable responses to management approaches [1, 2]. A prominent endotype of asthma is the presence of type 2 inflammation [3, 4]. Airway epithelial cells play pivotal roles in the initiation of type 2 inflammation by expressing interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP) [5-7]. These epithelial cell-derived cytokines act on innate immune cells including dendritic cells, group 2 innate lymphoid cells (ILC2s) and mast cells [8-15]. Recent identification of memory Th2 cells with high expression of receptor for IL-25, IL-33 and TSLP supports a role of these cytokines in adaptive immune responses in allergy [16, 17]. IL-25 [18, 19], IL-33 [20], and TSLP [11] have each been reported to be indispensable and sufficient for type 2 cytokine production, eosinophilic airway inflammation and AHR in certain mouse models. In human asthma, various expression patterns of these cytokines have been reported [21-25]. Although IL-25, IL-33 and TSLP are critical in type 2 airway inflammation, the upstream signaling pathway regulating their expression remains elusive.

When exposed to environmental stimuli, airway epithelial cells rapidly express danger signals such as adenosine triphosphate (ATP), uric acid to alert the immune system [26, 27]. Allergen exposure enhanced airway ATP concentration in human asthma and sensitized mice. Neutralizing airway ATP or blocking of purine signaling suppressed airway inflammation in allergen sensitized and challenged mice [28]. Extracellular ATP concentration is tightly controlled by ecto-nucleoside triphosphate diphosphohydrolases (ENTPD) [29]. CD39 (encoded by *ENTPD1*), catalyzing the degradation of extracellular ATP and ADP, is expressed in airway epithelial cells [30]. Inhibition of CD39 activity increased BALF ATP concentration and intensified ovalbumin-induced

bronchospasm in mice [31]. CD39-deficient mice exhibited worsened airway inflammation and

mucus overproduction after allergen sensitization and challenge [32], whereas the paradoxically

alleviated airway inflammation was also reported in CD39-dificient mice [33]. Recently, it is

reported that ATP serves as a sensor for an airborne allergen to trigger IL-33 release in airway

epithelial cells [34]. Together, these studies suggest that CD39-extracellular ATP axis may regulate

IL-25, IL-33 and TSLP in asthma.

MicroRNAs (miRNAs) regulate gene expression by promoting the catabolism of the target

transcripts as well as attenuating their translation. There are a growing body of evidence that

miRNAs play important roles in epithelial cell, ILC2 and Th2 cell differentiation and function in

asthma [35-38]. MiR-19a promotes IL-5, IL-13 expression in ILC2s and Th2 cells [37, 38]. Let-7

miRNA regulates IL-13 expression and allergic airway inflammation [39, 40]. The global

miRNAs expression in airway epithelial cells are altered in asthma [36, 41]. However, the

difference of epithelial miRNA expression between type 2-low and type 2-high asthma remains

unknown. We hypothesized that the differentially expressed epithelial miRNAs between the two

asthma subsets may contribute to IL-25, IL-33 and TSLP expression in asthma.

In this study, we profiled the epithelial miRNAs' expression in type 2-low and -high asthma

patients. We found that miR-206, the most highly expressed miRNA in type 2-high asthma relative

to type 2-low asthma, targets CD39-extracelluar ATP axis to regulate IL-25 and TSLP expression

in cultured bronchial epithelial cells. Airway ATP levels were increased and strongly correlated

with elevated IL-25 and TSLP expression in type 2-high asthma patients. In a mouse model of

asthma, manipulation of airway miR-206 expression altered Il-25, Il-33, Tslp expression, ILC2

expansion, and type 2 airway inflammation.

91   5

MATERIAL AND METHODS

Human subjects

We recruited 26 healthy control subjects and 57 asthma patients who were symptomatic, newly diagnosed and treatment-naïve. All subjects were Chinese and were recruited from Tongji Hospital. Subjects with asthma were diagnosed by a physician; had symptoms of episodic cough, wheeze and/or dyspnea; and had accumulated dosage of methacholine provoking a 20% fall (PD_{20}) of forced expiratory volume in the first second (FEV_1) < 2.505 mg and/or $\geq$12% increase in FEV_1 following inhalation of 200μg salbutamol. We recruited subjects who had never smoked or received inhaled or oral corticosteroid or leukotriene antagonist. Healthy control subjects had no respiratory symptoms, normal spirometric value and methacholine $PD_{20} \geq$ 2.505 mg.

For each subject, we recorded demographic information, performed spirometry, measured fractional exhaled nitric oxide (FeNO), collected induced sputum and BALF samples. We performed bronchoscopy with endobronchial epithelial brushing. Brushing techniques was described previously [42].

MicroRNA microarray

Total RNA from bronchial epithelial brushing samples from four type 2-low and four type 2-high asthma patients were extracted using TRIzol (Invitrogen). After passing RNA quantity measurement using the NanoDrop 1000, the samples were labeled using the miRCURY Hy3/Hy5 power labeling kit (Exiqon) and hybridized on miRCURY LNA microRNA array (7th generation, miRBase v18; Exiqon). The slides were scanned using Axon GenePix 4000B microarray scanner (Axon Instruments). Scanned images were then imported into GenePix Pro 6.0 software (Axon Instruments) for grid alignment and data extraction. We used median normalization method to

obtain "normalized data". Normalized data = (foreground - background) / median. In comparison,

genes with greater than 2-fold change and statistically significant difference between two groups

were considered to be differentially expressed.

HBE cell culture and treatment

Human bronchial epithelial (HBE) cells collected from heathy donors (n = 8) by bronchial

brushing technique were cultured at an air-liquid interface as previously described [43, 44].

Briefly, ten sites of the subsegmental bronchi of right middle and lower lobes were brushed. The

dissociated cells were recovered by vortexing the brush in ice-cold DMEM. The cells were

centrifuged, resuspended, then seeded into six-well plate coated with collagen I from rat tail

(Corning) and grown in bronchial epithelial cell medium (BEpiCM; ScienCell) with supplements.

Medium was changed every 48 h until cells were 90% confluent. Cells were then seeded on 1.1

cm^2 Transwell inserts (Corning) with 0.4 μm pores. Cells were submerged for the first 7 days in

BEpiCM (ScienCell) with supplements, and then the apical medium was removed to establish an

air-liquid interface that was maintained for the next 14 days. The basolateral medium was changed

to differentiation medium containing a 1:1 mixture of DMEM (Hyclone) and bronchial epithelial

cell growth medium (BEGM; Lonza) with supplements and 50 nM all-trans retinoic acid

(Sigma-Aldrich). Cells were stimulated with HDM (50 μg/ml; Greer Laboratories) and transfected

with control or miR-206 mimic, control or miR-206 inhibitor (RiboBio), scrambled or CD39

siRNA, empty or CD39 cDNA expression vector. Cells were also stimulated with HDM with or

without apyrase, ATPγS (Sigma-Aldrich).

Mouse model of allergic airway inflammation

The model was established by HDM sensitization and challenge. Briefly, female C57BL/6 mice

received intraperitoneal injection with 100µl of the solution of lyophilized HDM extract (0.1

mg/ml; Greer Laboratories) and Al $(OH)_3$ as an adjuvant on days 0, 7 and 14, and received 40µl

HDM solution (3 mg/ml) or saline intranasally on days 21, 22, and 23. MiR-206 agomir (5 nmol

in 40µl saline; RiboBio) or control agomir, or miR-206 antagomir (20 nmol in 40µl saline) or

control antagomir were administered intranasally on days 20 and 22. Twenty-four hours after the

last HDM challenge, respiratory resistance in response to a range of concentrations of intravenous

acetylcholine was measured using the forced oscillation technique with the FlexiVent system

(SCIREQ) as previously described [45].

Assessment of mouse airway inflammation

Cell counts for macrophages, eosinophils, lymphocytes, and neutrophils in bronchoalveolar lavage

fluid were performed as previously described [45]. Paraffin-embedded 5-µm lung sections were

stained with hematoxylin and eosin. The severity of peribronchial inflammation was scored by a

blinded observer using the following features: 0, normal; 1, few cells; 2, a ring of inflammatory

cells 1 cell layer deep; 3, a ring of inflammatory cells 2–4 cells deep; 4, a ring of inflammatory

cells of >4 cells deep.

Immunohistochemistry

152 Sections of mice lungs were stained with rabbit polyclonal CD39 (ENTPD1) antibody

153 (Proteintech). Antibodies were detected using the Real EnVision detection system (Dako

154 Diagnostics) according to instructions.

PAS staining

156 Mice lung sections were stained with periodic acid-schiff (PAS) (Goodbio Technology) for

157 detection of mucus. The number of PAS-staining-positive cells was counted in four random fields

158   for each lung section at ×200 magnification.

Quantitative polymerase chain reaction (PCR)

For quantification of hsa-miR-206 in epithelial brushings and HBE cells, mmu-miR-206

expression in mouse lungs, *CD39*, *IL-25*, *IL-33* (transcript without exons 3, 4), *TSLP* (long

isoform), *CLCA1*, *POSTN*, *SERPINB2* mRNA expression in epithelial brushings, and *Cd39*

mRNA expression in mouse lungs, total RNA was isolated and reverse transcribed. Quantitative

PCR were performed using an ABI Prism 7500 HT Fast Real-time PCR System (Applied

Biosystems). The cycle threshold (Ct) of each gene transcript was normalized to the Ct of U6, or

U48 for miRNA, and to β-actin or GAPDH for mRNA, respectively. Relative gene expression was

calculated by using the 2(-Delta Delta Ct) method [46]. The transcript levels of each gene are

expressed as relative to the median of healthy control subjects or the mean of control group and

log2 transformed. Primers for quantitative PCR were listed in Supplementary Table. The

stem-loop RT primer (ssD809230234), forward primer (ssD809230926) and reverse primer

(ssD089261711) for hsa-/ mmu-miR-206 were from RiboBio. Taqman primer and probe sets for

IL-25 (Hs00224471_m1), *TSLP* (long isoform; Hs01572933_m1), and *ACTB* (Hs99999903_m1)

were from Applied Biosystems. The transcripts for *IL-33* without exons 3, 4 were determined by

RNase H-dependent quantitative RT-PCR as reported by Gordon et al [47].

In situ hybridization

176   We performed in situ hybridization of mmu-miR-206 on paraffin-embedded sections using

177   mmu-miR-206 miRCURY LNA miRNA detection probe (Qiagen). The sequence of the probes for

178   mmu-miR-206 was 5'- CCACACACTTCCTTACATTCCA -3'.

Luciferase activity assay

180 Vector harboring wild-type, mutant CD39 3'-UTR or no 3'-UTR (control) were co-transfected

181 with miR-206 mimic or nontargeting control into BEAS-2B cells. Luciferase activity was detected

182 by dual luciferase reporter assay system (Promega). Normalized relative light units represent

183 firefly luciferase activity / renilla luciferase activity.

Western blotting

185 CD39 protein expression in cells was detected by monoclonal mouse-anti-human CD39 antibody

186 (clone OTI2B10, OriGene Technologies) using Western blotting as previously described [45].

ELISA

188 Human IL-25 (RayBiotech), IL-33, TSLP (R&D Systems) in supernatant from BALF and cell

189 culture medium, and mouse Il-4, Il-5, Il-13 (R&D Systems), Il-25, Il-33 (Thermo Fisher

190 Scientific), Tslp (R&D Systems) in BALF supernatant were measured by ELISA according to the

191 manufacturer's instructions. Mouse plasma IgE levels were determined by ELISA (Dakewe

192 Biotech. All samples and standards were measured in duplicate.

ATP measurements

194 To measure ATP levels in human BALF, ice-cold BALF samples were centrifuged at 4℃

195 immediately after collection and the supernatants were stored at −80℃. Supernatant of fresh mice

196 BALF and cell culture medium were analyzed immediately. ATP levels were measured using ATP

197 assay kit (Beyotime Biotechnology) according to instructions.

Flow cytometry

To analyze lung ILC2s, single cell suspensions of mouse lung tissue were incubated with cocktail

of biotin-conjugated monoclonal antibodies for lineage markers [CD5, CD11b, CD45R (B220),

Anti-Gr-1 (Ly-6G/C), 7-4, and Ter-119], and then mixed with Anti-Biotin MicroBeads (Miltenyi

Biotec). Lineage-negative lung cells were isolated with column placed in the magnetic field of a

MACS Separator (Miltenyi Biotec). Lineage-negative cells were stained with BV421-conjugated

Live/Dead Fixable Dead Cell Stain (Invitrogen), PerCP/Cy5.5-conjugated CD25 (clone PC61;

Biolegend), PE-conjugated CD127 (clone A7R34; Biolegend), FITC-conjugated T1/ST2 (clone

DJ8; MD bioscience), APC-conjugated Sca-1 (clone D7; Biolegend). The samples were analyzed

using EPICS-XL MCL flow cytometer (Beckman Coulter). Live lineage-negative

CD25+CD127+T1/ST2+Sca-1+ lymphocytes were identified as ILC2s. Data were analyzed with

FlowJo software (TreeStar).

Statistics

We analyzed data using Prism version 5 (GraphPad Software) and SPSS version 19 (SPSS

Inc.). For normally distributed data, we calculated means ± standard deviation (SD) and used

parametric tests (unpaired Student's t test or one-way ANOVA with Bonferroni's post hoc test).

For non-normally distributed data, we calculated medians (with interquartile ranges) and used

non-parametric tests (Mann-Whitney test or one-way ANOVA with Bonferroni's post hoc test).

We analyzed correlation using Spearman's rank order correlation. Values of $P < 0.05$ were

considered statistically significant.

Study approvals

Human and mouse studies were approved by the ethics committee of Tongji Hospital, Tongji

Medical College, Huazhong University of Science and Technology. Participants gave informed

consent.

RESULTS

Differentially expressed epithelial miRNAs including miR-206 between type 2-low and –high

asthma.

We profiled the miRNA expression of bronchial epithelial brushings from type 2-low asthmatics

($n = 4$), type 2-high asthmatics ($n = 4$) using miRNA microarray. The type 2 status of asthma was

defined by the expression of the type 2 signature genes (*CLCA1*, *POSTN*, and *SERPINB10*) in the

epithelial brushings as previously reported [3, 48]. We found that 20 miRNAs were significantly

differentially expressed between the two subsets of asthma (Figure 1A). The data are available at

GEO (http://www.ncbi.nlm.nih.gov/geo/, accession number GSE142237). Of note, miR-206 was

the most highly expressed miRNA in type 2-high asthma relative to type 2-low asthma. Several

other differentially expressed miRNAs including miR-31-5p, miR-146a-5p, miR-146b-5p,

miR-221-3p have been implicated in asthma pathogenesis [49-51]. Epithelial miR-221-3p

expression was shown to be associated with airway eosinophilia and the expression of type 2

signature genes in asthma patients in our previous study [52].

We next examined the expression of miR-206 in a cohort including type 2-low asthmatics ($n =$

20), type 2-high asthmatics ($n = 37$), and healthy controls ($n = 26$) using quantitative PCR.

Compared with type 2-low asthmatics, type 2-high asthmatics had lower methacholine PD_{20},

higher eosinophil counts in induced sputum and blood, higher fractional exhaled nitric oxide

(FeNO) and serum IgE levels (Table 1). Consistent with the microarray data, epithelial miR-206

expression was higher in type 2-high asthma relative to type 2-low asthma. However, compared to

healthy controls, epithelial miR-206 transcript levels were decreased in both type 2-low and type

2-high asthma (Figure 1B). Our data suggest that epithelial miR-206 expression is downregulated

in asthma and associates with airway type 2 inflammation.

The expression of CD39, a target of miR-206, is upregulated in airway epithelial cells in

asthma

We predicted the candidate target genes of miR-206 by using online algorithms

(DIANA-microT, miRanda, miRWalk, PicTar and TargetScan). CD39, the ectoenzyme catalyzing

the degradation of extracellular ATP and ADP, is one of the candidate targets. The 3'-untranslated

region (UTR) of CD39 contains nucleotides matching the seed sequence of hsa-miR-206 (Figure

2A). Transfection of miR-206 mimic decreased the luciferase activity when co-transfected with

the vector harboring wild-type CD39 3'-UTR, but had no effect on the luciferase activity when

co-transfected with the vector containing mutant 3'-UTR or empty vector (Figure 2B). This

indicates that miR-206 may directly act on the 3'-UTR of CD39 mRNA. Further, inhibition of

miR-206 expression enhanced CD39 mRNA and protein expression, whereas overexpression of

miR-206 suppressed CD39 expression (Figure 2C-E). These data indicate that CD39 is a target

gene of miR-206.

In human asthma, we found that CD39 transcript levels were significantly increased in

bronchial brushings from type 2-low and -high asthma patients compared to controls. Moreover,

epithelial CD39 expression was lower in type 2-high asthma relative to type 2-low asthma (Figure

2F). In support of CD39 as a target of miR-206, epithelial CD39 transcript levels negatively

correlated with epithelial miR-206 expression (Figure 2G) in asthma patients.

Extracellular ATP accumulation induces miR-206 downregulation and CD39 upregulation in

human bronchial epithelial cells

It was reported that BALF ATP concentration was increased in asthma patients after allergen

provocation [28]. In BALF from our symptomatic and treatment-naïve asthma patients, we

measured ATP using luciferase bioluminescence. BALF ATP levels were markedly increased in

both type 2-low and –high asthmatics compared to controls (Figure 3A). Moreover, BALF ATP

levels were higher in type 2-high asthma relative to type 2-low asthma. This suggests that

extracellular ATP is accumulated in the airways of symptomatic asthma patients.

Extracellular ATP accumulation upregulates CD39 expression in airway epithelial cells, which

catalyzes the degradation of excessive extracellular ATP to maintain the homeostasis of

microenvironment [53]. To determine whether miR-206-CD39 axis responds to extracellular ATP

accumulation, we performed air-liquid interface culture of human bronchial epithelial (HBE) cells

from healthy donors. House dust mite (HDM), the most clinically relevant allergen, rapidly

increased ATP concentration in culture medium within 2 min. The ATP concentration peaked at

1-2 h, and declined to baseline by 6h (Figure 3B). HDM exposure decreased miR-206 expression

from 2 h to 12 h, with a maximum inhibition at 6 h (Figure 3C), and increased CD39 mRNA from

2 h to 12 h, peaking at 6 h (Figure 3D). Furthermore, elimination of extracellular ATP by

pretreatment with apyrase suppressed HDM-induced miR-206 downregulation and CD39

upregulation at 6 h in HBE cells (Figure 3E and G). Exogenous ATP analog, ATPγS, directly

decreased miR-206 expression and increased CD39 expression, and intensified HDM-induced

miR-206 downregulation and CD39 upregulation (Figure 3F and H). Together, our data suggest

that allergen-induced acute accumulation of extracellular ATP downregulates miR-206 and

upregulates CD39 expression in airway epithelial cells. This may represent a protective

mechanism to eliminate excessive extracellular ATP.

Higher ATP levels associate with elevated IL-25 and TSLP expression in type 2-high asthma

Allergen stimulates the release of ATP as an alarmin from airway epithelial cells to induce the

expression of IL-33 [34]. We next examined the airway IL-25, IL-33 and TSLP expression in

bronchial epithelial brushings and BALF using quantitative PCR and ELISA, respectively.

Epithelial *IL25* transcript levels and BALF IL-25 protein levels were significantly higher in type

2-high asthma when compared with type 2-low asthma and controls (Figure 4A, 4D). There were

multiple splice variants of *IL-33* transcript, and the protein encoded by the *IL33* transcript without

exons 3 and 4 is secreted as active cytokine [47]. We examined the expression of *IL33* transcript

without exons 3 and 4 in bronchial epithelial brushings using RNase H-dependent quantitative

PCR as previously reported [47]. However, there were no significant difference in this *IL33*

transcript among the two asthma subsets and controls. Neither did we detect significant difference

in IL-33 protein levels in BALF (Figure 4B, 4E). TSLP has short and long isoforms, and the long

isoform is induced during inflammation [54]. We found that the long *TSLP* transcripts and BALF

TSLP protein levels were higher in type 2-high asthma compared to type 2-low asthma and control

subjects (Figure 4C, 4F). Our data suggest that airway expression of IL-25, TSLP whereas not

IL-33 is elevated in type 2-high asthma.

Importantly, BALF ATP levels were strongly correlated with BALF IL-25 and TSLP protein

levels (Figure 4G-H). This indicates that the more prominent accumulation of airway ATP may be

responsible for elevated IL-25 and TSLP expression in type 2-high asthma.

Extracellular ATP is essential for allergen-induced IL-25 and TSLP expression in human

bronchial epithelial cells.

We next examined the role of extracellular ATP in HDM-induced IL-25, IL-33 and TSLP

expression in HBE cells cultured on an air-liquid interface. We found that HDM stimulation

increased *IL-25* mRNA expression in HBE cells and IL-25 protein levels in basal-lateral medium,

peaking at 2 h and 6 h, respectively (Figure 5A and D). HDM also increased TSLP (the long

transcript variant) mRNA and protein expression, peaking at 1 h and 6 h, respectively (Figure 5C

and F). However, HDM stimulation did not alter the expression of IL-33 (the transcript without

exons 3, 4) mRNA or protein (Figure 5B and E). Elimination of extracellular ATP by CD39

overexpression or by using apyrase suppressed HDM-induced IL-25 and TSLP protein expression

at 6 h (Figure 5G-J). In contrast, enhancing extracellular ATP by CD39 knockdown or by adding

ATPγS further increased HDM-induced IL-25 and TSLP protein expression (Figure 5K-N). These

data suggest that HDM-induced acute accumulation of extracellular ATP is required for IL-25 and

TSLP upregulation in airway epithelial cells.

MiR-206 regulates allergen-induced IL-25 and TSLP expression in bronchial epithelial cells

via targeting CD39-extracellular ATP axis

We next examined whether miR-206 regulates IL-25 and TSLP expression via targeting

CD39-extracellular ATP axis in HDM-stimulated HBE cells. Inhibition of miR-206 expression by

transfection with miR-206 inhibitor increased baseline and HDM-induced CD39 expression.

Importantly, inhibition of miR-206 expression decreased the ATP concentration, and suppressed

HDM-induced IL-25 and TSLP protein expression in the medium (Figure 6A-D). In contrast,

miR-206 overexpression by transfection with miR-206 mimic suppressed baseline and

HDM-induced CD39 expression, enhanced extracellular ATP, and further enhanced HDM-induced

IL-25 and TSLP protein expression (Figure 6E-H). Our data indicates that miR-206 regulates

epithelial IL-25 and TSLP expression by targeting CD39-extracellular ATP axis.

Airway epithelial miR-206 regulates CD39 expression, BALF ATP concentration in a murine

model of allergic airway disease

We investigated the role of epithelial miR-206 in a murine model of allergic airway inflammation of C57BL/6 mice sensitized and challenged with HDM. Using quantitative PCR, in situ hybridization, immunohistochemistry and luciferase bioluminescence, we found that HDM challenge decreased epithelial miR-206 expression, increased CD39 expression, and markedly enhanced BALF ATP levels compared to control mice. Inhibition of airway miR-206 expression by intranasal administration of miR-206 antagomir further enhanced HDM-induced CD39 expression whereas suppressed HDM-induced BALF ATP accumulation (Figure 7A-D). In contrast, airway overexpression of miR-206 by intranasal administration of miR-206 agomir significantly suppressed HDM-induced CD39 expression, and further enhanced HDM-induced increase of ATP concentrations (Figure 7E-I). These data suggest that epithelial miR-206 targets CD39-extracellular ATP axis in the airway of a murine model of allergic airway disease.

Airway miR-206 antagonism suppresses HDM-induced AHR, airway eosinophilia, mucus overproduction and type 2 cytokines expression in mice

In the murine model of allergic airway disease, HDM sensitization and challenge increased airway resistance to methacholine, induced the infiltration of inflammatory cells around airways, increased airway mucus-producing cells and plasma IgE levels. Inhibition of airway miR-206 expression by transfection with miR-206 antagomir significantly suppressed HDM-induced AHR, airway eosinophilic inflammation and mucus overproduction (Figure 8A-F). In contrast, airway miR-206 overexpression by transfection with miR-206 agomir further enhanced HDM-induced AHR, airway eosinophilia and mucus overproduction (Supplementary Figure A-F). Moreover, airway miR-206 antagonism suppressed HDM-induced expression of type 2 cytokines including

Il-4, Il-5 and Il-13, and decreased plasma IgE levels (Figure 8G-J), whereas miR-206

overexpression further enhanced HDM-induced expression of type 2 cytokines in mice lungs and

plasma IgE levels (Supplementary Figure G-J). Our data indicates that epithelial miR-206 play an

essential role in allergic airway disease by regulating type 2 immune response.

Airway miR-206 antagonism suppresses Il-25, Il-33, Tslp expression and ILC2s expansion in

mice

Since ILC2s play a pivotal role in type 2 response upon activation by IL-25 IL-33 and TSLP, we

further examined the effect of airway miR-206 manipulation on Il-25, Il-33, Tslp expression and

ILC2s expansion in mice. HDM sensitization and challenge increased Il-25, Il-33 and Tslp protein

levels in BALF (Figure 9A-F). Meanwhile, HDM sensitization and challenge significantly

increased the number of ILC2s (Lin$^-$CD25$^+$CD127$^+$ST2$^+$Sca-1$^+$, gating strategy in Figure 9G) in

single-cell suspension of lungs by flow cytometric analysis (Figure 9H-K). Airway miR-206

antagonism suppressed HDM-induced Il-25, Il-33, and Tslp expression (Figure 9A-C) and ILC2s

expansion (Figure 9H and J), whereas miR-206 overexpression further enhanced HDM-induced

Il-25, Il-33 and Tslp expression (Figure 9D-F) and ILC2s expansion in mice lungs (Figure 9I and

K). This suggests that epithelial miR-206 regulates HDM-induced Il-25, Il-33 and Tslp expression

and ILC2s expansion in mouse models.

DISCUSSION

In the present study, we reported that epithelial miR-206 was differentially expressed between type 2-low and -high asthma patients who were symptomatic and treatment-naïve. Type 2-high asthma patients had higher miR-206 expression, lower epithelial CD39 expression, elevated BALF ATP levels, and higher epithelial IL-25, TSLP expression as compared with type 2-low asthma. Of note, BALF ATP levels strongly correlated with airway IL-25 and TSLP expression in asthma patients. The associations between these measurements were functionally validated in primary culture of HBE cells, and in a murine model of allergic airway inflammation.

MiRNAs play essential roles in the pathogenesis of asthma [39, 40, 55, 56]. So far, the differentially expressed epithelial miRNAs between type 2-low and high asthma remains unknown. We identified miR-206 as the most highly miRNA in type 2-high asthma relative to type 2-low asthma. However, compared to control subjects, miR-206 expression was downregulated in both asthma subsets. MiR-206 expression was also decreased in cultured HBE cells exposed to HDM and in the airways of mouse sensitized and challenged with HDM. Our findings are consistent with the report that miR-206 expression was decreased in airway wall of a mouse model of childhood allergic asthma [57]. Recent studies showed that miR-206 expression was also decreased in mouse models of occupational asthma [58, 59]. In human, it was reported that circulating miR-206 was useful to predict childhood asthma exacerbation [60], and plasma miR-206 expression differed between asthmatics with higher and lower blood eosinophil counts [61]. However, the mechanism underlying the less reduction of epithelial miR-206 in type 2-high asthma relative to type 2-low asthma requires further investigation.

To explore the role of miR-206 in asthma, we verified that CD39, an ecto-nucleotidase

degrading ATP, was a target of miR-206. So far, there is no studies addressing the regulation of

airway CD39 in human asthma. Previous reports regarding the role of CD39 in animal asthma

models were conflicting [32, 33]. We demonstrated that CD39 expression was increased in airway

epithelium in human asthma and in mice sensitized and challenged with HDM. Consistent with

higher expression of miR-206 in type 2-high asthma, CD39 expression was lower in type 2-high

asthma relative to type 2-low asthma.

Extracellular ATP serves as a danger signal to alert the immune system of tissue damage. In our

cohort of symptomatic and treatment-naïve asthma patients, BALF ATP concentrations were

significantly increased, especially in type 2-high asthma patients. This is consistent with a

previous report that allergen provocation enhanced airway BALF ATP accumulation in asthma

patients [28]. The elevated airway ATP levels in our asthma patients might be due to exposure to

environmental aeroallergen including HDM and/or airway virus infections, the main triggers of

asthma exacerbation [12, 62]. It was reported that rhinovirus infection stimulated bronchial

smooth muscle cells to release ATP [63], and influenza A virus infection increased BALF ATP

levels in mice [64].

In our *in vitro* system, we demonstrated that HDM-induced acute extracellular ATP

accumulation was responsible for miR-206 downregulation and CD39 upregulation in HBE cells

on an air-liquid interface. Since CD39 catalyzes ATP degradation, the CD39 upregulation in

asthma patients and in HDM-exposed HBE cells may represent an inhibitory feedback response to

excessive ATP, by which striving to maintain airway homeostasis.

In human asthma, we previously reported that epithelial *IL-25* mRNA expression was

upregulated in a subset of asthma patients featured by type 2 inflammation [42]. Here, in a

different cohort of asthmatics, we reported that airway expression of IL-25 and TSLP whereas not

IL-33 was elevated in type 2-high asthma using ELISA and qPCR. The Taqman qPCR primers and

probes were previously reported for the *IL-33* isoform without exons 3 and 4, and the long isoform

of *TSLP*, and these isoforms were associated with type 2 inflammation [47, 54]. So far, there have

been few head-to-head studies of IL-25, IL-33 and TSLP expression in human asthma. Various

expression patterns of these cytokines were reported in different populations. In Korean, plasma

IL-25 whereas not IL-33 or TSLP was increased in patients with aspirin-exacerbated respiratory

disease characterized by asthma, nasal polyps and chronic eosinophilic sinusitis [21]. Elevated

IL-25, but not IL-33 or TSLP mRNA, was reported in sputum cells from uncontrolled asthmatics

in Belgium [22]. In contrast, increased expression of IL-33 and TSLP whereas not IL-25 was

reported in asthma patients in London [23], Poland [24], and New York [25]. This suggests that

ethnicity and region should be considered in studies on these cytokines. Recently, a new concept

"regiotype" was introduced for allergic diseases, referring to regional difference between

endotypes due to different allergens and other environmental influences [2]. In chronic

rhinosinusitis with nasal polyps (CRSwNP), a disease related to asthma, various expression

patterns of IL-25, IL-33 and TSLP in different population and regions have been described.

Reports of IL-25 upregulation in CRSwNP came from Asian countries including Korea [65],

Japan [66] and China [67], whereas negative results of IL-25 were from USA [68], Australia [69]

and Turkey [70]. Our data of airway IL-25, IL-33 and TSLP expression in asthma patients will

provide evidence for the novel therapies targeting these cytokines in China.

The upstream signaling pathway regulating the expression of epithelial IL-25 and TSLP remains

largely unknown. Here we reported that BALF ATP concentrations strongly correlated with airway

IL-25 and TSLP expression. *In vitro*, allergen-induced acute accumulation of extracellular ATP was required and sufficient for IL-25 and TSLP expression. Further, epithelial miR-206 regulated IL-25 and TSLP expression by targeting CD39-extracellular ATP axis both *in vitro* and *in vivo*. HDM sensitization and challenge decreased airway miR-206 expression while increased Cd39 expression, BALF ATP concentration, Il-25, Il-33, Tslp expression, and ILC2s expansion in mice. Airway miR-206 antagonism before HDM challenge suppressed Il-25, Il-33, Tslp expression, ILC2s expansion, type 2 cytokine expression, and the cardinal features of asthma in mice. On the other hand, miR-206 overexpression had opposite effects.

As summarized in Figure 10, our findings suggest that epithelial miR-206 is downregulated in both asthma subsets. Compared with type 2-low asthma, less reduction of epithelial miR-206 resulted in higher miR-206, lower CD39 expression and impaired capacity to eliminate extracellular ATP in type 2-high asthma. Consequently, more extracellular ATP is accumulated leading to higher expression of IL-25, TSLP and more prominent type 2 inflammation in type 2-high asthma. Alternative cascades may also explain the effect of miR-206 perturbation on type 2 response in mice. For example, increased extracellular ATP can directly activate other immune cells including dendritic cells [28]. ATP can also promote dendritic cell-driven Th2 sensitization by inducing epithelial cells to release inflammatory cytokines [71, 72].

In conclusion, epithelial miR-206 regulates airway IL-25 and TSLP expression and type 2 inflammation in asthma via targeting CD39-extracellular ATP axis. This pathway contributes, at least in part, to the development of human type 2-high asthma and represents a novel therapeutic target for this endotype.

Conflicts of interests: The authors have declared that no conflict of interest exists.

Funding: This work was supported by National Natural Science Foundation of China (grant 91742108, 81670019, 81800026, 81600023), National Key Research and Development Program of China (2016YFC1304400), and Hubei Province Natural Science Foundation (grant 2017CFA016).

Acknowledgements: The authors thank all participants in this study; Xiaoling Rao and Mei Liu for bronchoscopy support; Wang Ni, Shixin Chen and Kun Zhang for spirometry measurement.

Author contributions: G.Z. designed the research, conceived of the manuscript and had primary responsibility for writing. K.Z., Y.F., Y.L., W.W., C.C., D.C., S.C., J.G., and G.C. performed experiments. K.Z., Y.F., Y.L., L.Y., D.C., and G.Z. analyzed data. K.Z., Y.F., Y.L., L.Y., D.C., and G.Z. interpreted results of experiments. K.Z., Y.F., and G.Z. prepared figures and drafted manuscript. G.Z. edited and revised manuscript. All authors reviewed and approved the manuscript.

REFERENCES

1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012: 18(5):
716-725.

2. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of
allergic diseases. *J Clin Invest* 2019: 129(4): 1493-1503.

3. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type
2-driven inflammation defines major subphenotypes of asthma. *American journal of respiratory and critical care*
medicine 2009: 180(5): 388-395.

4. Peebles RS, Jr., Aronica MA. Proinflammatory Pathways in the Pathogenesis of Asthma. *Clin Chest Med* 2019:
40(1): 29-50.

5. Hammad H, Lambrecht BN. Barrier Epithelial Cells and the Control of Type 2 Immunity. *Immunity* 2015: 43(1):
29-40.

6. Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. *J Clin*
Invest 2019: 129(4): 1441-1451.

7. Hiemstra PS, McCray PB, Jr., Bals R. The innate immune function of airway epithelial cells in inflammatory lung
disease. *Eur Respir J* 2015: 45(4): 1150-1162.

8. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD,
Zurawski G, Leach MW, Gorman DM, Rennick DM. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies
in vivo. *Immunity* 2001: 15(6): 985-995.

9. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman
DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2
and induces T helper type 2-associated cytokines. *Immunity* 2005: 23(5): 479-490.

10. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K,
Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ.
Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol* 2002:
3(7): 673-680.

11. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation
in an asthma model. *J Exp Med* 2005: 202(6): 829-839.

12. Bloodworth MH, Rusznak M, Pfister CC, Zhang J, Bastarache L, Calvillo SA, Chappell JD, Boyd KL, Toki S,
Newcomb DC, Stier MT, Zhou W, Goleniewska K, Moore ML, Hartert TV, Niswender KD, Peebles RS, Jr. Glucagon-like
peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology.
The Journal of allergy and clinical immunology 2018: 142(2): 683-687 e612.

13. Vercelli D. When Innate Responses Matter: ILC2s Loom Large in Allergic Airway Inflammation. *American journal*
of respiratory and critical care medicine 2017: 195(12): 1544-1546.

14. Causton B, Pardo-Saganta A, Gillis J, Discipio K, Kooistra T, Rajagopal J, Xavier RJ, Cho JL, Medoff BD. CARMA3
Mediates Allergic Lung Inflammation in Response to Alternaria alternata. *Am J Respir Cell Mol Biol* 2018: 59(6):
684-694.

15. Altman MC, Lai Y, Nolin JD, Long S, Chen CC, Piliponsky AM, Altemeier WA, Larmore M, Frevert CW, Mulligan MS,
Ziegler SF, Debley JS, Peters MC, Hallstrand TS. Airway epithelium-shifted mast cell infiltration regulates asthmatic
inflammation via IL-33 signaling. *J Clin Invest* 2019: 129(11): 4979-4991.

16. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, Hippe A, Corrigan CJ, Dong C, Homey B, Yao Z,
Ying S, Huston DP, Liu YJ. IL-25 augments type 2 immune responses by enhancing the expansion and functions of
TSLP-DC-activated Th2 memory cells. *J Exp Med* 2007: 204(8): 1837-1847.

17.   Endo Y, Hirahara K, Iinuma T, Shinoda K, Tumes DJ, Asou HK, Matsugae N, Obata-Ninomiya K, Yamamoto H,
Motohashi S, Oboki K, Nakae S, Saito H, Okamoto Y, Nakayama T. The interleukin-33-p38 kinase axis confers memory
T helper 2 cell pathogenicity in the airway. *Immunity* 2015: 42(2): 294-308.
18.   Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN. Blocking
IL-25 prevents airway hyperresponsiveness in allergic asthma. *The Journal of allergy and clinical immunology* 2007:
120(6): 1324-1331.
19.   Suzukawa M, Morita H, Nambu A, Arae K, Shimura E, Shibui A, Yamaguchi S, Suzukawa K, Nakanishi W, Oboki K,
Kajiwara N, Ohno T, Ishii A, Korner H, Cua DJ, Suto H, Yoshimoto T, Iwakura Y, Yamasoba T, Ohta K, Sudo K, Saito H,
Okumura K, Broide DH, Matsumoto K, Nakae S. Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F,
is crucial for murine asthma. *J Immunol* 2012: 189(7): 3641-3652.
20.   Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. *Nat Rev
Immunol* 2010: 10(2): 103-110.
21.   Lee JU, Chang HS, Lee HJ, Bae DJ, Son JH, Park JS, Choi JS, Hwang HG, Park CS. Association of interleukin-25
levels with development of aspirin induced respiratory diseases. *Respir Med* 2017: 123: 71-78.
22.   Seys SF, Grabowski M, Adriaensen W, Decraene A, Dilissen E, Vanoirbeek JA, Dupont LJ, Ceuppens JL, Bullens
DM. Sputum cytokine mapping reveals an 'IL-5, IL-17A, IL-25-high' pattern associated with poorly controlled asthma.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2013: 43(9):
1009-1017.
23.   Li Y, Wang W, Lv Z, Chen Y, Huang K, Corrigan CJ, Ying S. Elevated Expression of IL-33 and TSLP in the Airways of
Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. *J Immunol* 2018: 200(7): 2253-2262.
24.   Gluck J, Rymarczyk B, Kasprzak M, Rogala B. Increased Levels of Interleukin-33 and Thymic Stromal
Lymphopoietin in Exhaled Breath Condensate in Chronic Bronchial Asthma. *Int Arch Allergy Immunol* 2016: 169(1):
51-56.
25.   Bleck B, Kazeros A, Bakal K, Garcia-Medina L, Adams A, Liu M, Lee RA, Tse DB, Chiu A, Grunig G, Egan JP, 3rd,
Reibman J. Coexpression of type 2 immune targets in sputum-derived epithelial and dendritic cells from asthmatic
subjects. *The Journal of allergy and clinical immunology* 2015: 136(3): 619-627 e615.
26.   O'Grady SM, Patil N, Melkamu T, Maniak PJ, Lancto C, Kita H. ATP release and Ca2+ signalling by human
bronchial epithelial cells following Alternaria aeroallergen exposure. *J Physiol* 2013: 591(18): 4595-4609.
27.   Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, Rogers N, Osorio F, Reis e Sousa C,
Hammad H, Lambrecht BN. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled
antigens and inflammatory mediator of allergic asthma. *Immunity* 2011: 34(4): 527-540.
28.   Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D,
Di Virgilio F, Virchow JC, Jr., Lambrecht BN. Extracellular ATP triggers and maintains asthmatic airway inflammation by
activating dendritic cells. *Nat Med* 2007: 13(8): 913-919.
29.   Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5'-nucleotidase and nonspecific alkaline phosphatase.
Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. *J Biol Chem* 2003: 278(15): 13468-13479.
30.   Leal DB, Streher CA, Neu TN, Bittencourt FP, Leal CA, da Silva JE, Morsch VM, Schetinger MR. Characterization of
NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes.
Biochim Biophys Acta 2005: 1721(1-3): 9-15.
31.   Chavez J, Vargas MH, Rebollar-Ayala DC, Diaz-Hernandez V, Cruz-Valderrama JE, Flores-Soto E, Flores-Garcia M,
Jimenez-Vargas NN, Barajas-Lopez C, Montano LM. Inhibition of extracellular nucleotides hydrolysis intensifies the
allergic bronchospasm. A novel protective role of ectonucleotidases. *Allergy* 2013: 68(4): 462-471.
32.   Li P, Gao Y, Cao J, Wang W, Chen Y, Zhang G, Robson SC, Wu Y, Yang J. CD39+ regulatory T cells attenuate allergic
airway inflammation. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical*

Immunology 2015: 45(6): 1126-1137.

33.   Idzko M, C KA, Muller T, Durk T, Grimm M, Baudiss K, Vieira RP, Cicko S, Boehlke C, Zech A, Sorichter S, Pelletier J,

Sevigny J, Robson SC. Attenuated allergic airway inflammation in Cd39 null mice. *Allergy* 2013: 68(4): 472-480.

34.   Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an

airborne allergen and triggers IL-33 release and innate Th2-type responses. *J Immunol* 2011: 186(7): 4375-4387.

35.   Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. *Nat Rev*

Immunol 2013: 13(9): 666-678.

36.   Solberg OD, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Barczak AJ, Zlock LT, Blagev DP,

Finkbeiner WE, Ansel KM, Arron JR, Erle DJ, Woodruff PG. Airway epithelial miRNA expression is altered in asthma.

American journal of respiratory and critical care medicine 2012: 186(10): 965-974.

37.   Singh PB, Pua HH, Happ HC, Schneider C, von Moltke J, Locksley RM, Baumjohann D, Ansel KM. MicroRNA

regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation. *J Exp Med* 2017: 214(12):

3627-3643.

38.   Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, Wang Y, Pua HH, Baumjohann D, Montoya MM,

Panduro M, Remedios KA, Huang X, Fahy JV, Arron JR, Woodruff PG, Ansel KM. A microRNA upregulated in asthma

airway T cells promotes TH2 cytokine production. *Nat Immunol* 2014: 15(12): 1162-1170.

39.   Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C, Benham AL, Kim J, Soibam B, Harris RA,

Coarfa C, Zariff A, Milosavljevic A, Batts LM, Kheradmand F, Gunaratne PH, Corry DB. Proinflammatory role for let-7

microRNAS in experimental asthma. *J Biol Chem* 2010: 285(39): 30139-30149.

40.   Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, Ghosh B. Let-7 microRNA-mediated

regulation of IL-13 and allergic airway inflammation. *The Journal of allergy and clinical immunology* 2011: 128(5):

1077-1085 e1071-1010.

41.   Huo X, Zhang K, Yi L, Mo Y, Liang Y, Zhao J, Zhang Z, Xu Y, Zhen G. Decreased epithelial and plasma miR-181b-5p

expression associates with airway eosinophilic inflammation in asthma. *Clinical and experimental allergy : journal of*

the British Society for Allergy and Clinical Immunology 2016: 46(10): 1281-1290.

42.   Cheng D, Xue Z, Yi L, Shi H, Zhang K, Huo X, Bonser LR, Zhao J, Xu Y, Erle DJ, Zhen G. Epithelial interleukin-25 is a

key mediator in Th2-high, corticosteroid-responsive asthma. *American journal of respiratory and critical care*

medicine 2014: 190(6): 639-648.

43.   Kelsen SG, Mardini IA, Zhou S, Benovic JL, Higgins NC. A technique to harvest viable tracheobronchial epithelial

cells from living human donors. *Am J Respir Cell Mol Biol* 1992: 7(1): 66-72.

44.   Zhen G, Park SW, Nguyenvu LT, Rodriguez MW, Barbeau R, Paquet AC, Erle DJ. IL-13 and epidermal growth factor

receptor have critical but distinct roles in epithelial cell mucin production. *Am J Respir Cell Mol Biol* 2007: 36(2):

244-253.

45.   Yi L, Cheng D, Zhang K, Huo X, Mo Y, Shi H, Di H, Zou Y, Zhang H, Zhao J, Xu Y, Erle DJ, Zhen G. Intelectin

contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic

dermatitis. *Mucosal Immunol* 2017: 10(6): 1491-1503.

46.   Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the

2(-Delta Delta C(T)) Method. *Methods* 2001: 25(4): 402-408.

47.   Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, Wesolowska-Andersen A,

Gonzalez JR, MacLeod HJ, Christian LS, Yuan S, Barry L, Woodruff PG, Ansel KM, Nocka K, Seibold MA, Fahy JV.

Alternative splicing of interleukin-33 and type 2 inflammation in asthma. *Proceedings of the National Academy of*

Sciences of the United States of America 2016: 113(31): 8765-8770.

48.   Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, Woodruff PG. A qPCR-based metric of Th2

airway inflammation in asthma. *Clinical and translational allergy* 2013: 3(1): 24.

49.   Tasena H, Boudewijn IM, Faiz A, Timens W, Hylkema MN, Berg M, Ten Hacken NHT, Brandsma CA, Heijink IH, van
den Berge M. MiR-31-5p: A shared regulator of chronic mucus hypersecretion in asthma and chronic obstructive
pulmonary disease. *Allergy* 2020: 75(3): 703-706.

50.   Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. MicroRNA-146a and
microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. *American journal of*
physiology Lung cellular and molecular physiology 2014: 307(9): L727-734.

51.   Perry MM, Baker JE, Gibeon DS, Adcock IM, Chung KF. Airway smooth muscle hyperproliferation is regulated by
microRNA-221 in severe asthma. *Am J Respir Cell Mol Biol* 2014: 50(1): 7-17.

52.   Zhang K, Liang Y, Feng Y, Wu W, Zhang H, He J, Hu Q, Zhao J, Xu Y, Liu Z, Zhen G. Decreased epithelial and sputum
miR-221-3p associates with airway eosinophilic inflammation and CXCL17 expression in asthma. *American journal of*
physiology Lung cellular and molecular physiology 2018: 315(2): L253-L264.

53.   Burch LH, Picher M. E-NTPDases in human airways: Regulation and relevance for chronic lung diseases.
Purinergic signalling 2006: 2(2): 399-408.

54.   Fornasa G, Tsilingiri K, Caprioli F, Botti F, Mapelli M, Meller S, Kislat A, Homey B, Di Sabatino A, Sonzogni A, Viale
G, Diaferia G, Gori A, Longhi R, Penna G, Rescigno M. Dichotomy of short and long thymic stromal lymphopoietin
isoforms in inflammatory disorders of the bowel and skin. *The Journal of allergy and clinical immunology* 2015:
136(2): 413-422.

55.   Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates
IL-12p35 expression. *J Immunol* 2009: 182(8): 4994-5002.

56.   Malmhall C, Alawieh S, Lu Y, Sjostrand M, Bossios A, Eldh M, Radinger M. MicroRNA-155 is essential for
T(H)2-mediated allergen-induced eosinophilic inflammation in the lung. *The Journal of allergy and clinical*
immunology 2014: 133(5): 1429-1438, 1438 e1421-1427.

57.   Collison A, Siegle JS, Hansbro NG, Kwok CT, Herbert C, Mattes J, Hitchins M, Foster PS, Kumar RK. Epigenetic
changes associated with disease progression in a mouse model of childhood allergic asthma. *Dis Model Mech* 2013:
6(4): 993-1000.

58.   Lin CC, Law BF, Siegel PD, Hettick JM. Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel
biomarkers for 4,4'-methylene diphenyl diisocyanate exposure. *Biomarkers* 2019: 24(1): 76-90.

59.   Lin CC, Law BF, Hettick JM. Acute 4,4'-Methylene Diphenyl Diisocyanate Exposure-Mediated Downregulation of
miR-206-3p and miR-381-3p Activates Inducible Nitric Oxide Synthase Transcription by Targeting Calcineurin/NFAT
Signaling in Macrophages. *Toxicol Sci* 2020: 173(1): 100-113.

60.   Kho AT, McGeachie MJ, Moore KG, Sylvia JM, Weiss ST, Tantisira KG. Circulating microRNAs and prediction of
asthma exacerbation in childhood asthma. *Respir Res* 2018: 19(1): 128.

61.   Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, Ishmael FT. Circulating microRNAs as
biomarkers in patients with allergic rhinitis and asthma. *The Journal of allergy and clinical immunology* 2016: 137(5):
1423-1432.

62.   Leung TF, To MY, Yeung AC, Wong YS, Wong GW, Chan PK. Multiplex molecular detection of respiratory
pathogens in children with asthma exacerbation. *Chest* 2010: 137(2): 348-354.

63.   Calven J, Akbarshahi H, Menzel M, Ayata CK, Idzko M, Bjermer L, Uller L. Rhinoviral stimuli, epithelial factors and
ATP signalling contribute to bronchial smooth muscle production of IL-33. *J Transl Med* 2015: 13: 281.

64.   Wolk KE, Lazarowski ER, Traylor ZP, Yu EN, Jewell NA, Durbin RK, Durbin JE, Davis IC. Influenza A virus inhibits
alveolar fluid clearance in BALB/c mice. *American journal of respiratory and critical care medicine* 2008: 178(9):
969-976.

65.   Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, Kong IG, Mo JH, Yang MS, Jin HR, Park JW, Kim DW. IL-25 as a
novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. *The Journal of allergy and clinical*

immunology 2015: 135(6): 1476-1485 e1477.

66.   Iinuma T, Okamoto Y, Yamamoto H, Inamine-Sasaki A, Ohki Y, Sakurai T, Funakoshi U, Yonekura S, Sakurai D,

Hirahara K, Nakayama T. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis.

Ann Allergy Asthma Immunol 2015: 114(4): 289-298.

67.   Chen F, Hong H, Sun Y, Hu X, Zhang J, Xu G, Zhao W, Li H, Shi J. Nasal interleukin 25 as a novel biomarker for

patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness: A pilot study. *Ann Allergy*

Asthma Immunol 2017: 119(4): 310-316 e312.

68.   Ogasawara N, Klingler AI, Tan BK, Poposki JA, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS,

Conley DB, Kern RC, Schleimer RP, Kato A. Epithelial activators of type 2 inflammation: Elevation of thymic stromal

lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. *Allergy* 2018:

73(11): 2251-2254.

69.   Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, Vreugde S. Association between group 2

innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. *Allergy* 2014: 69(9): 1154-1161.

70.   Ozturan A, Eyigor H, Eyigor M, Osma U, Yilmaz MD, Selcuk OT, Renda L, Gultekin M. The role of IL-25 and IL-33 in

chronic rhinosinusitis with or without nasal polyps. *Eur Arch Otorhinolaryngol* 2017: 274(1): 283-288.

71.   Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC, Jr., Luttmann W,

Norgauer J, Di Virgilio F, Idzko M. The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8

secretion. *Am J Respir Cell Mol Biol* 2005: 33(6): 601-609.

72.   Douillet CD, Robinson WP, 3rd, Milano PM, Boucher RC, Rich PB. Nucleotides induce IL-6 release from human

airway epithelia via P2Y2 and p38 MAPK-dependent pathways. *American journal of physiology Lung cellular and*

molecular physiology 2006: 291(4): L734-746.

 FIGURE LEGENDS:

Figure 1. Epithelial miRNA expression profiling reveals differentially expressed miRNAs

including miR-206 between type 2-low and –high asthma. (A) Twenty differentially expressed

epithelial miRNAs between subjects with type 2-low asthma (n = 4) and type 2-high asthma (n = 4)

were identified using microarrays. Each column represents data from one subject. Colors represent

fold change relative to the mean value of type 2-low asthma. (B) miR-206 transcript levels in

bronchial brushings from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37)

and healthy controls (n = 26) were determined by quantitative PCR. The transcript levels are

expressed as relative to the median value of healthy controls and log2 transformed. One-way

ANOVA with Bonferroni's post hoc test was performed.

Figure 2. The expression of CD39, a target of miR-206, is increased in airway epithelial cells

in human asthma. (A) The 3'-UTR of CD39 contains region that matches the seed sequence of

hsa-miR-206. (B) 3'-UTR luciferase report assay with vector harboring wild-type (WT), mutant

CD39 3'-UTR or no 3'-UTR (control) co-transfected with miR-206 mimic or non-targeting control.

Luciferase activity was measured by dual-luciferase reporter assay system. The firefly luciferase

activity was normalized to renilla luciferase activity. n = 4 per group. (C, D) CD39 transcript

levels in BEAS-2B cells after transfection with miR-206 mimic (*C*) or inhibitor (*D*) were

determined by quantitative PCR. The transcript levels are expressed as relative to the mean value

of control group (two-tailed Student's *t* test). n = 4 per group. Data are mean ± SD. (E) CD39

protein expression in BEAS-2B cells after transfection with miR-206 mimic and inhibitor were

determined by Western blotting. (F) CD39 transcript levels in bronchial brushings from type 2-low

asthma patients (n = 20), type 2-high asthma patients (n=37) and healthy controls (n = 26) were

determined by quantitative PCR. The transcript levels are expressed as relative to the median

value of healthy controls and log2 transformed (one-way ANOVA with Bonferroni's post hoc test).

(G) Spearman's rank order correlation assay between epithelial CD39 and miR-206 transcript

levels in all asthma patients (n = 57).

Figure 3. Acute extracellular ATP accumulation is responsible for allergen-induced miR-206

downregulation and CD39 upregulation in bronchial epithelial cells. (A) ATP levels in BALF

from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37), and healthy

controls (n = 26) were determined by luciferase bioluminescence. BALF ATP levels were

expressed as luminometer counts (one-way ANOVA with Bonferroni's post hoc test). (B) ATP

concentration in culture medium collected at indicated time points after HDM stimulation was

measured by luciferase bioluminescence. (C, D) Transcript levels of miR-206 (*C*) and CD39 (*D*)

in HBE cells harvested at indicated time points after HDM stimulation were determined by

quantitative PCR. n = 4-6 per time point combined from 2 experiments using HBE cells from 2

healthy donors. Data are mean ± SD. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with

Bonferroni's post hoc test). (E-F) MiR-206 transcript levels in HBE cells pretreated with apyrase

or saline for 2 h before adding HDM and stimulation for 6 h (*E*), and treated with ATPγS or saline

with or without HDM for 6h (*F*). (G, H) CD39 transcript levels in HBE cells pretreated with

apyrase or saline for 2 h before adding HDM and stimulation for 6 h (*G*), and treated with ATPγS

or saline with or without HDM for 6h (*H*). The transcript levels are expressed as relative to the

mean value of control group and log2 transformed. n = 4-6 wells per group combined from 2

experiments using HBE cells from 2 healthy donors. Data are mean ± SD. *$P<0.05$; **$P<0.01$;

***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test).

Figure 4. **Airway IL-25 and TSLP expression is elevated in type 2-high asthma, and correlates with BALF ATP levels in asthma.** (A-C) The transcripts of *IL-25* (*A*), *IL-33* without exons 3, 4 (*B*), and long isoform of *TSLP* (*C*) in bronchial epithelial brushings from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using quantitative PCR with Taqman primers and probes. For detection of *IL-33* transcript without exons 3 and 4, RNase H-dependent quantitative PCR was performed. The transcript levels are expressed as relative to the median value of healthy controls and log2 transformed. (D-F) IL-25 (*D*), IL-33 (*E*) and TSLP (*F*) protein levels in BALF from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using ELISA. One-way ANOVA with Bonferroni's post hoc test was performed. (G-H) Spearman's rank order correlation assays between BALF ATP levels and BALF IL-25 protein levels (*G*), and TSLP protein levels (*H*).

Figure 5. Extracellular ATP is required and sufficient for IL-25 and TSLP expression in bronchial epithelial cells. (A-C) The transcripts of *IL-25* (*A*), *IL-33* without exons 3, 4 (*B*), and the long isoform of TSLP (*C*) in HBE cells harvested at indicated time points after HDM stimulation were determined by quantitative PCR. (D-F) IL-25 (*D*), IL-33 (*E*) and TSLP (*F*) protein levels in culture medium collected at indicated time points after HDM stimulation were determined by ELISA. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test). n = 5-6 wells per time points combined from 2 experiments using HBE cells from 2 healthy donors. (G, H) IL-25 (*G*) and TSLP (*H*) protein levels in culture medium after transfection with empty or CD39 expression vector and stimulated with or without HDM for 6 h were determined by ELISA. (I, J) IL-25 (*I*) and TSLP (*J*) protein levels in culture medium after pretreatment with apyrase or saline and stimulated with or without HDM for 6 h were determined

by ELISA. (K, L) IL-25 (*K*) and TSLP (*L*) protein levels in culture medium after transfection with scrambled or CD39 siRNA and stimulated with or without HDM for 6 h were determined by ELISA. (M, N) IL-25 (*M*) and TSLP (*N*) protein levels in culture medium after treatment with ATPγS or saline and with or without HDM for 6h were determined by ELISA. n = 4 wells per group. Data are mean ± SD. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test). n = 4-6 wells per group combined from 2 experiments using HBE cells from 2 healthy donors.

Figure 6. MiR-206 regulates allergen-induced IL-25 and TSLP expression via targeting CD39 - extracellular ATP axis in bronchial epithelial cells. (A) CD39 transcript levels in HBE cells transfected with control or miR-206 inhibitor and stimulated with or without HDM for 6 h were determined by quantitative PCR. (B) ATP concentration in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (C, D) IL-25 (*C*), and TSLP (*D*) protein levels in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were determined by ELISA. (E) CD39 transcript levels in HBE cells transfected with control or miR-206 mimic and stimulated with or without HDM for 6 h were determined by quantitative PCR. (F) ATP concentration in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (G, H) IL-25 (*G*), and TSLP (*H*) protein levels in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were determined by ELISA. n = 4 wells per group. Data are mean ± SD. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test). n = 5-6 wells per group combined from 2 experiments using HBE cells

from 2 healthy donors.

Figure 7. Epithelial miR-206 targets CD39-extracellular ATP axis in a murine model of

allergic airway inflammation. (A) Experimental schedule as described in Methods. (B-D)

MiR-206 (*B*) and CD39 (*C*) transcript levels in lungs, and ATP levels in BALF (*D*) were

determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally

administered with control or miR-206 antagomir and challenged with HDM or saline. (E-G)

MiR-206 (*E*) and CD39 (*F*) transcript levels in lungs, and ATP levels in BALF (*G*) were

determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally

administered with control or miR-206 agomir and challenged with HDM or saline. The transcript

level is expressed as relative to the mean value of control group and log2 transformed. BALF ATP

levels were expressed as luminometer counts. n = 6 - 10 mice per group combined from 2

independent experiments. Data are mean ± SD. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$ (one-way

ANOVA with Bonferroni's post hoc test). (H, I) Representative images of *in situ* hybridization of

miR-206 (*H*), and immunohistochemistry of CD39 (*I*) in lung sections of mice intranasally

administered with control or miR-206 agomir and challenged with HDM or saline. Scale bar = 50

μm.

Figure 8. Airway miR-206 antagonism suppresses HDM-induced AHR, airway inflammation,

mucus overproduction and type 2 response in mice. (A) Respiratory resistance in response to

different concentration of intravenous acetycholine at 24 h after the last HDM or saline challenge

in mice intranasally administered with control or miR-206 antagomir. (B) Inflammatory scores of

lung sections from mice intranasally administered with control or miR-206 antagomir and

challenged with HDM or saline were calculated as described in Methods. (C) Counts for

macrophages, eosinophils, lymphocytes and neutrophils in BALF. (D) H&E staining of

representative lung sections. (E) PAS staining for mucus in representative lung sections. (F) The

numbers of PAS-staining-positive cells were counted in four random fields for each lung section at

×200 magnification. (G-I) The protein levels of IL-4 (*G*), IL-5 (*H*), IL-13 (*I*) in BALF were

determined by ELISA. (J) Plasma IgE levels in peripheral blood were determined by ELISA. n =

6-10 mice per group combined from 2 independent experiments. Data are mean ± SD. *$P<0.05$;

**$P<0.01$; ***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test). Scale bar = 50μm.

Figure 9. Perturbation of airway miR-206 expression alters HDM-induced Il-25, Il-33, Tslp

expression and ILC2 expansion in mice lung. (A-C) Il-25 (*A*), Il-33 (*B*) and Tslp (*C*) protein

levels in BALF were determined by ELISA in mice intranasally administered with control or

miR-206 antagomir and challenged with HDM or saline. (D-F) Il-25 (*D*), Il-33 (*E*) and Tslp

protein levels (*F*) in BALF were determined by ELISA in mice intranasally administered with

control or miR-206 agomir and challenged with HDM or saline. n = 6-10 mice per group

combined from 2 independent experiments. (G) Single cell suspensions of mouse lung tissue were

incubated with cocktail of biotin-conjugated antibodies for lineage markers and mixed with

Anti-Biotin MicroBeads to isolate lineage-negative lung cells. ILC2s in mice lungs were

enumerated via flow cytometry analysis with lineage-negative lung cells using the following

gating strategy: live, single, CD25$^+$ CD127$^+$ ST2$^+$ Sca-1$^+$ cells. (H, J) Representative flow

cytometric plots (*H*) and numbers of ILC2s (*J*) from lungs of mice intranasally administered with

control or miR-206 antagomir and challenged with HDM or saline. (I, K) Representative flow

cytometric plots (*I*) and numbers of ILC2s (*K*) from lungs of mice intranasally administered with

control or miR-206 agomir and challenged with HDM or saline. n = 4 -6 per group combined from

2 experiments. Data are mean ± SD. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with

Bonferroni's post hoc test).

Figure 10. **Scheme for the signaling pathway regulating IL-25 and TSLP expression in**

airway epithelial cells in type 2-low and type 2-high asthma. Allergen stimulates the rapid

release of ATP from epithelial cells. Extracellular ATP serves as an alarmin to induce the

expression of innate cytokines IL-25, TSLP. Meanwhile, acute accumulation of extracellular ATP

decreases epithelial miR-206 expression, which upregulates CD39 expression to eliminate

excessive ATP. Epithelial miR-206 is decreased in both type 2-low and type 2-high asthma.

Compared with type 2-low asthma, less reduction of epithelial miR-206 resulted in higher

miR-206, lower CD39 expression and impaired capacity to eliminate extracellular ATP in type

2-high asthma. Consequently, more extracellular ATP is accumulated which leads to higher

expression of IL-25, TSLP and more prominent type 2 inflammation in type 2-high asthma.

Table 1. **Subjects Characteristics***

	Healthy control subjects	Type 2-low asthma patients	Type 2-high asthma patients	*p* value, type 2 low vs. high
Sample size, n	26	20	37	—
Age, yr	35.0 (28.8-42.3)	40.0 (32.3-49.5)	42.0 (31.5-50.0)	0.90
Sex, M:F (%F)	9:17 (65.3)	6:14 (70.0)	15:22 (59.5)	0.57
Body mass index	22.7 (20.6-23.8)	23.5 (21.4-25.3)	22.1 (20.6-24.0)	0.15
FEV_1, % predicted	99.0 (96.0-105.7)	82.4 (68.8-90.2)	81.6 (71.4-88.2)	0.82
Methacholine PD_{20}, mg	2.5 (2.5-2.5)	0.16 (0.04-0.25)	0.01 (0.01-0.05)	0.0009
Sputum eosinophil, %	0.3 (0-1.0)	1.8 (1.0-11.3)	16.0 (8.4-22.2)	0.0004
Blood eosinophil, $\times 10^9$/L	0.06 (0.04-0.12)	0.12 (0.07-0.23)	0.33 (0.19-0.57)	0.0003
FeNO, ppb	14.0 (11.0-17.0)	32.8 (20.3-43.7)	94.7(65.0-134.6)	< 0.0001
Serum IgE, IU/ml	27.3 (16.9-41.3)	95.0 (11.9-187.0)	150.1(72.1-335.5)	0.03
Atopic, n (%)	3 (11.5)	18 (90.0)	37 (100.0)	0.12

828   * Data are median (interquartile range) unless otherwise specified. *p* values comparing type 2-low with

829   type 2-high asthma were calculated by Fisher's exact test, or Mann-Whitney U test, as appropriate.

830   Definition of abbreviation: PD_{20} = provocative dosage required to cause a 20% decline in FEV_1. The

831   minimal and maximal provocative dosages were 0.01 and 2.505 mg, respectively.

Figure 1. Epithelial miRNA expression profiling reveals differentially expressed miRNAs including miR-206 between type 2-low and –high asthma. (A) Twenty differentially expressed epithelial miRNAs between subjects with type 2-low asthma (n = 4) and type 2-high asthma (n = 4) were identified using microarrays. Each column represents data from one subject. Colors represent fold change relative to the mean value of type 2-low asthma. (B) miR-206 transcript levels in bronchial brushings from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37) and healthy controls (n = 26) were determined by quantitative PCR. The transcript levels are expressed as relative to the median value of healthy controls and log2 transformed. One-way ANOVA with Bonferroni's post hoc test was performed.

Figure 2. The expression of CD39, a target of miR-206, is increased in airway epithelial cells in human asthma. (A) The 3'-UTR of CD39 contains region that matches the seed sequence of hsa-miR-206. (B) 3'-UTR luciferase report assay with vector harboring wild-type (WT), mutant CD39 3'-UTR or no 3'-UTR (control) co-transfected with miR-206 mimic or non-targeting control. Luciferase activity was measured by dual-luciferase reporter assay system. The firefly luciferase activity was normalized to renilla luciferase activity. n = 4 per group. (C, D) CD39 transcript levels in BEAS-2B cells after transfection with miR-206 mimic (*C*) or inhibitor (*D*) were determined by quantitative PCR. The transcript levels are expressed as relative to the mean value of controls (two-tailed Student's *t* test). n = 4 per group. Data are mean ± SD. (E) CD39 protein expression in BEAS-2B cells after transfection with miR-206 mimic and inhibitor were determined by Western blotting. (F) CD39 transcript levels in bronchial brushings from type 2-low asthma patients (n = 20), type 2-high asthma patients (n=37) and healthy controls (n = 26) were determined by quantitative PCR. The transcript levels are expressed as relative to the median value of controls and log2 transformed (one-way ANOVA with Bonferroni's post hoc test). (G) Spearman's rank order correlation assay between epithelial CD39 and miR-206 transcript levels in all asthma patients (n = 57).

Figure 3. Acute extracellular ATP accumulation is responsible for allergen-induced miR-206 downregulation and CD39 upregulation in bronchial epithelial cells. (A) ATP levels in BALF from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37), and healthy controls (n = 26) were determined by luciferase bioluminescence. BALF ATP levels were expressed as luminometer counts (one-way ANOVA with Bonferroni's post hoc test). (B) ATP concentration in culture medium collected at indicated time points after HDM stimulation was measured by luciferase bioluminescence. (C, D) Transcript levels of miR-206 (*C*) and CD39 (*D*) in HBE cells harvested at indicated time points after HDM stimulation were determined by quantitative PCR. n = 4-6 per time point combined from 2 experiments using HBE cells from 2 healthy donors. Data are mean ± SD. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test). (E-F) MiR-206 transcript levels in HBE cells pretreated with apyrase or saline for 2 h before adding HDM and stimulation for 6 h (*E*), and treated with ATPγS or saline with or without HDM for 6h (*F*). (G, H) CD39 transcript levels in HBE cells pretreated with apyrase or saline for 2 h before adding HDM and stimulation for 6 h (*G*), and treated with ATPγS or saline with or without HDM for 6h (*H*). The transcript levels are expressed as relative to the mean value of control group and log2 transformed. n = 4-6 wells per group combined from 2 experiments using HBE cells from 2 healthy donors. Data are mean ± SD. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test).

Figure 4. Airway IL-25 and TSLP expression is elevated in type 2-high asthma, and correlates with BALF ATP levels in asthma. (A-C) The transcripts of *IL-25* (*A*), *IL-33* without exons 3, 4 (*B*), and long isoform of *TSLP* (*C*) in bronchial epithelial brushings from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using quantitative PCR with Taqman primers and probes. For detection of *IL-33* transcript without exons 3 and 4, RNase H-dependent quantitative PCR was performed. The transcript levels are expressed as relative to the median value of healthy controls and log2 transformed. (D-F) IL-25 (*D*), IL-33 (*E*) and TSLP (*F*) protein levels in BALF from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using ELISA. One-way ANOVA with Bonferroni's post hoc test was performed. (G-H) Spearman's rank order correlation assays between BALF ATP levels and BALF IL-25 protein levels (*G*), and TSLP protein levels (*H*).

Figure 5. Extracellular ATP is required and sufficient for IL-25 and TSLP expression in bronchial epithelial cells. (A-C) The transcripts of IL-25 (A), IL-33 without exons 3, 4 (B), and the long isoform of TSLP (C) in HBE cells harvested at indicated time points after HDM stimulation were determined by quantitative PCR. (D-F) IL-25 (D), IL-33 (E) and TSLP (F) protein levels in culture medium collected at indicated time points after HDM stimulation were determined by ELISA. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test). n = 5-6 wells per time points combined from 2 experiments using HBE cells from 2 healthy donors. (G, H) IL-25 (G) and TSLP (H) protein levels in culture medium after transfection with empty or CD39 expression vector and stimulated with or without HDM for 6 h were determined by ELISA. (I, J) IL-25 (I) and TSLP (J) protein levels in culture medium after pretreatment with apyrase or saline and stimulated with or without HDM for 6 h were determined by ELISA. (K, L) IL-25 (K) and TSLP (L) protein levels in culture medium after transfection with scrambled or CD39 siRNA and stimulated with or without HDM for 6 h were determined by ELISA. (M, N) IL-25 (M) and TSLP (N) protein levels in culture medium after treatment with ATPγS or saline and with or without HDM for 6h were determined by ELISA. n = 4 wells per group. Data are mean ± SD. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test). n = 4-6 wells per group combined from 2 experiments using HBE cells from 2 healthy donors.

Figure 6. MiR-206 regulates allergen-induced IL-25 and TSLP expression via targeting CD39 - extracellular ATP axis in bronchial epithelial cells. (A) CD39 transcript levels in HBE cells transfected with control or miR-206 inhibitor and stimulated with or without HDM for 6 h were determined by quantitative PCR. (B) ATP concentration in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (C, D) IL-25 (*C*), and TSLP (*D*) protein levels in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were determined by ELISA. (E) CD39 transcript levels in HBE cells transfected with control or miR-206 mimic and stimulated with or without HDM for 6 h were determined by quantitative PCR. (F) ATP concentration in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (G, H) IL-25 (*G*), and TSLP (*H*) protein levels in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were determined by ELISA. n = 4 wells per group. Data are mean ± SD. *$P<0.05$; **$P<0.01$; ***$P<0.001$ (one-way ANOVA with Bonferroni's post hoc test). n = 5-6 wells per group combined from 2 experiments using HBE cells from 2 healthy donors.

Figure 7. Epithelial miR-206 targets CD39-extracellular ATP axis in a murine model of allergic airway inflammation. (A) Experimental schedule as described in Methods. (B-D) MiR-206 (*B*) and CD39 (*C*) transcript levels in lungs, and ATP levels in BALF (*D*) were determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally administered with control or miR-206 antagomir and challenged with HDM or saline. (E-G) MiR-206 (*E*) and CD39 (*F*) transcript levels in lungs, and ATP levels in BALF (*G*) were determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. The transcript level is expressed as relative to the mean value of control group and log2 transformed. BALF ATP levels were expressed as luminometer counts. n = 6 - 10 mice per group combined from 2 independent experiments. Data are mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA with Bonferroni's post hoc test). (H, I) Representative images of *in situ* hybridization of miR-206 (*H*), and immunohistochemistry of CD39 (*I*) in lung sections of mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. Scale bar = 50 μm.

Figure 8. Airway miR-206 antagonism suppresses HDM-induced AHR, airway inflammation, mucus overproduction and type 2 response in mice. (A) Respiratory resistance in response to different concentration of intravenous acetycholine at 24 h after the last HDM or saline challenge in mice intranasally administered with control or miR-206 antagomir. (B) Inflammatory scores of lung sections from mice intranasally administered with control or miR-206 antagomir and challenged with HDM or saline were calculated as described in Methods. (C) Counts for macrophages, eosinophils, lymphocytes and neutrophils in BALF. (D) H&E staining of representative lung sections. (E) PAS staining for mucus in representative lung sections. (F) The numbers of PAS-staining-positive cells were counted in four random fields for each lung section at ×200 magnification. (G-I) The protein levels of IL-4 (*G*), IL-5 (*H*), IL-13 (*I*) in BALF were determined by ELISA. (J) Plasma IgE levels in peripheral blood were determined by ELISA. n = 6-10 mice per group combined from 2 independent experiments. Data are mean ± SD. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test). Scale bar = 50 μm.

Figure 9. Perturbation of airway miR-206 expression alters HDM-induced Il-25, Il-33, Tslp expression and ILC2 expansion in mice lung. (A-C) Il-25 (*A*), Il-33 (*B*) and Tslp (*C*) protein levels in BALF were determined by ELISA in mice intranasally administered with control or miR-206 antagomir and challenged with HDM or saline. (D-F) Il-25 (*D*), Il-33 (*E*) and Tslp protein levels (*F*) in BALF were determined by ELISA in mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. n = 6-10 mice per group combined from 2 independent experiments. (G) Single cell suspensions of mouse lung tissue were incubated with cocktail of biotin-conjugated antibodies for lineage markers and mixed with Anti-Biotin MicroBeads to isolate lineage-negative lung cells. ILC2s in mice lungs were enumerated via flow cytometry analysis with lineage-negative lung cells using the following gating strategy: live, single, CD25+ CD127+ ST2+ Sca-1+ cells. (H, J) Representative flow cytometric plots (*H*) and numbers of ILC2s (*J*) from lungs of mice intranasally administered with control or miR-206 antagomir and challenged with HDM or saline. (I, K) Representative flow cytometric plots (*I*) and numbers of ILC2s (*K*) from lungs of mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. n = 4 -6 per group combined from 2 experiments. Data are mean ± SD. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA with Bonferroni's post hoc test).

Figure 10. Scheme for the signaling pathway regulating IL-25 and TSLP expression in airway epithelial cells in type 2-low and type 2-high asthma. Allergen stimulates the rapid release of ATP from epithelial cells. Extracellular ATP serves as an alarmin to induce the expression of innate cytokines IL-25, TSLP. Meanwhile, acute accumulation of extracellular ATP decreases epithelial miR-206 expression, which upregulates CD39 expression to eliminate excessive ATP. Epithelial miR-206 is decreased in both type 2-low and type 2-high asthma. Compared with type 2-low asthma, less reduction of epithelial miR-206 resulted in higher miR-206, lower CD39 expression and impaired capacity to eliminate extracellular ATP in type 2-high asthma. Consequently, more extracellular ATP is accumulated which leads to higher expression of IL-25, TSLP and more prominent type 2 inflammation in type 2-high asthma.